RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …

KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell
lung cancer (NSCLC) in Western countries. Of the various KRAS mutants, KRAS G12C is the …

Resistance to inactive state-selective RASG12C inhibitors frequently entails accumulation of
RASGTP, rendering effective inhibition of active RAS potentially desirable. Here, we …

Summary KRAS G12C inhibitors (adagrasib and sotorasib) have shown clinical promise in
targeting KRAS G12C-mutated lung cancers; however, most patients eventually develop …

Non–small lung cancers (NSCLC) frequently (∼ 30%) harbor KRAS driver mutations, half of
which are KRAS G12C. KRAS-mutant NSCLC with comutated STK11 and/or KEAP1 is …

KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …

The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in
pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients …

Abstract Purpose of Review Although the recent development of direct KRASG12C inhibitors
(G12Ci) has improved outcomes in KRAS mutant cancers, responses occur only in a fraction …

Lung cancer, predominantly non-small cell lung cancer (NSCLC), remains a significant
global health challenge, with limited therapeutic options for patients with KRAS-mutated …

Simple Summary Advances in next-generation sequencing have initiated a paradigm shift in
cancer treatment, transitioning from traditional, organ-specific protocols to precision …